Bevacizumab biosimilar (bevacizumab‐awwb) is safe in the treatment of retinopathy of prematurity-Reference-Cited by-同舟云学术

Bevacizumab biosimilar (bevacizumab‐awwb) is safe in the treatment of retinopathy of prematurity

Published:2024-09-09 Issue: Volume: Page:
ISSN:1442-6404
Container-title:Clinical & Experimental Ophthalmology
language:en
Short-container-title:Clinical Exper Ophthalmology

Author:

Liu Cindy Yue‐Ying¹^ORCID,Hong Zixin²,Dai Shuan¹³⁴^ORCID,Sheth Shivanand²,Shah Shaheen¹

Affiliation:

1. Department of Ophthalmology Queensland Children's Hospital South Brisbane Queensland Australia

2. Department of Ophthalmology The Royal Children's Hospital Melbourne Parkville Victoria Australia

3. Faculty of Medicine University of Queensland Brisbane Queensland Australia

4. Menzies Health Institute Queensland Griffith University Gold Coast Queensland Australia

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ceo.14439

Reference5 articles.

1. A network meta‐analysis of retreatment rates following bevacizumab, ranibizumab, aflibercept, and laser for retinopathy of prematurity;Chang E;Ophthalmology,2022

2. Anti‐vascular endothelial growth factor biosimilars in ophthalmology;Kaiser PK;Retina,2022

3. Initial experience with biosimilar bevacizumab‐bvzr for intravitreal use in children: a case series and literature review;Jung EE;Ophthalmic Surg Lasers Imaging Retina,2023

4. The Commonwealth of Australia.Parliamentary Debates House of Representatives; 18 October 2021. Accessed 23 July 2024.https://parlinfo.aph.gov.au/parlInfo/download/chamber/hansardr/25164/toc_pdf/House%20of%20Representatives_2021_10_18_Official.pdf;fileType=application%2Fpdf

5. Efficacy of an Indian bevacizumab BIOSimilar (BEVATAS) for type 1 and aggressive posterior retinopathy of prematurity (BIOS‐ROP study);Chakraborty S;Clin Ophthalmol,2024